Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 29 studies | 35% ± 17% | |
mast cell | 23 studies | 38% ± 15% | |
plasma cell | 20 studies | 41% ± 17% | |
fibroblast | 20 studies | 36% ± 15% | |
smooth muscle cell | 17 studies | 33% ± 12% | |
pericyte | 16 studies | 36% ± 17% | |
oligodendrocyte | 16 studies | 50% ± 17% | |
endothelial cell | 16 studies | 38% ± 15% | |
microglial cell | 14 studies | 47% ± 18% | |
monocyte | 12 studies | 31% ± 12% | |
basal cell | 12 studies | 28% ± 11% | |
myeloid cell | 12 studies | 32% ± 14% | |
adipocyte | 11 studies | 54% ± 17% | |
plasmablast | 10 studies | 44% ± 23% | |
astrocyte | 10 studies | 31% ± 16% | |
classical monocyte | 9 studies | 26% ± 8% | |
glutamatergic neuron | 9 studies | 45% ± 24% | |
B cell | 8 studies | 20% ± 4% | |
oligodendrocyte precursor cell | 8 studies | 27% ± 9% | |
epithelial cell | 7 studies | 33% ± 13% | |
GABAergic neuron | 7 studies | 33% ± 13% | |
IgG plasma cell | 7 studies | 34% ± 10% | |
respiratory goblet cell | 6 studies | 35% ± 13% | |
hepatocyte | 6 studies | 62% ± 29% | |
club cell | 6 studies | 26% ± 9% | |
ciliated cell | 6 studies | 23% ± 9% | |
IgA plasma cell | 6 studies | 41% ± 10% | |
dendritic cell | 5 studies | 23% ± 4% | |
natural killer cell | 5 studies | 19% ± 2% | |
neuron | 5 studies | 40% ± 21% | |
memory B cell | 5 studies | 19% ± 3% | |
cardiac muscle cell | 5 studies | 47% ± 13% | |
endothelial cell of vascular tree | 5 studies | 30% ± 5% | |
type I pneumocyte | 5 studies | 21% ± 5% | |
connective tissue cell | 5 studies | 26% ± 7% | |
alveolar macrophage | 5 studies | 40% ± 19% | |
type II pneumocyte | 5 studies | 34% ± 8% | |
pancreatic A cell | 4 studies | 71% ± 18% | |
naive B cell | 4 studies | 21% ± 5% | |
luminal cell of prostate epithelium | 4 studies | 42% ± 12% | |
muscle cell | 4 studies | 31% ± 12% | |
erythrocyte | 4 studies | 45% ± 18% | |
myofibroblast cell | 4 studies | 28% ± 7% | |
leukocyte | 4 studies | 31% ± 8% | |
T cell | 3 studies | 23% ± 4% | |
squamous epithelial cell | 3 studies | 35% ± 21% | |
type B pancreatic cell | 3 studies | 43% ± 13% | |
mononuclear phagocyte | 3 studies | 29% ± 13% | |
abnormal cell | 3 studies | 37% ± 26% | |
mucosal invariant T cell | 3 studies | 23% ± 6% | |
serous secreting cell | 3 studies | 31% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
lymphocyte | 3 studies | 27% ± 7% | |
CD4-positive helper T cell | 3 studies | 23% ± 4% | |
innate lymphoid cell | 3 studies | 22% ± 6% | |
conventional dendritic cell | 3 studies | 24% ± 2% | |
gamma-delta T cell | 3 studies | 28% ± 8% | |
cholangiocyte | 3 studies | 52% ± 28% | |
granulocyte | 3 studies | 36% ± 5% | |
neutrophil | 3 studies | 23% ± 9% | |
enteroendocrine cell | 3 studies | 35% ± 5% | |
adventitial cell | 3 studies | 39% ± 13% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 25% ± 3% | |
keratinocyte | 3 studies | 29% ± 11% | |
interneuron | 3 studies | 31% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 14 studies | 42% ± 20% | |
lung | 9 studies | 27% ± 8% | |
liver | 4 studies | 44% ± 19% | |
heart | 4 studies | 32% ± 10% | |
uterus | 4 studies | 18% ± 2% | |
prostate | 4 studies | 26% ± 10% | |
pancreas | 3 studies | 58% ± 9% | |
kidney | 3 studies | 16% ± 1% | |
eye | 3 studies | 25% ± 9% | |
adipose | 3 studies | 37% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 9582.46 | 242 / 245 | 100% | 80.24 | 501 / 502 |
pancreas | 100% | 8942.53 | 328 / 328 | 98% | 36.50 | 175 / 178 |
lung | 100% | 8249.92 | 576 / 578 | 98% | 40.30 | 1134 / 1155 |
esophagus | 98% | 7611.90 | 1421 / 1445 | 99% | 40.64 | 182 / 183 |
liver | 100% | 9225.27 | 226 / 226 | 97% | 45.12 | 395 / 406 |
breast | 99% | 6672.67 | 453 / 459 | 96% | 32.48 | 1078 / 1118 |
thymus | 99% | 4422.91 | 644 / 653 | 94% | 19.65 | 567 / 605 |
bladder | 100% | 4570.71 | 21 / 21 | 88% | 21.46 | 446 / 504 |
stomach | 99% | 8713.31 | 357 / 359 | 83% | 15.96 | 237 / 286 |
brain | 82% | 2999.75 | 2170 / 2642 | 99% | 33.22 | 699 / 705 |
skin | 100% | 10642.89 | 1806 / 1809 | 74% | 13.92 | 350 / 472 |
intestine | 87% | 3176.68 | 839 / 966 | 80% | 14.23 | 421 / 527 |
uterus | 60% | 1962.98 | 102 / 170 | 89% | 33.62 | 409 / 459 |
kidney | 61% | 2166.51 | 54 / 89 | 82% | 24.56 | 735 / 901 |
adrenal gland | 58% | 2081.99 | 149 / 258 | 73% | 26.51 | 167 / 230 |
blood vessel | 100% | 17173.65 | 1333 / 1335 | 0% | 0 | 0 / 0 |
ovary | 74% | 5023.59 | 134 / 180 | 24% | 2.72 | 105 / 430 |
adipose | 99% | 9780.21 | 1187 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 44.75 | 44 / 45 |
spleen | 95% | 4882.90 | 230 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 34.13 | 26 / 29 |
heart | 81% | 4642.83 | 700 / 861 | 0% | 0 | 0 / 0 |
muscle | 78% | 4758.30 | 624 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 39% | 2242.86 | 358 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 2.71 | 20 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0042795 | Biological process | snRNA transcription by RNA polymerase II |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0008023 | Cellular component | transcription elongation factor complex |
GO_0005515 | Molecular function | protein binding |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
Gene name | ELL2 |
Protein name | Elongation factor for RNA polymerase II 2 RNA polymerase II elongation factor ELL2 |
Synonyms | |
Description | FUNCTION: Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III . Plays a role in immunoglobulin secretion in plasma cells: directs efficient alternative mRNA processing, influencing both proximal poly(A) site choice and exon skipping, as well as immunoglobulin heavy chain (IgH) alternative processing. Probably acts by regulating histone modifications accompanying transition from membrane-specific to secretory IgH mRNA expression. . |
Accessions | A0A0U1RR08 H0Y8G1 ENST00000513343.1 O00472 D6RC27 ENST00000635633.1 ENST00000508757.1 ENST00000237853.9 [O00472-1] |